Share
- Release Date: 11/01/13 16:09
- Summary: GENERAL: BLT: A new 2013 research report extends the benefit of BLIS K12
- Price Sensitive: No
- Download Document 2.93KB
BLT
11/01/2013 14:09
GENERAL
REL: 1409 HRS BLIS Technologies Limited
GENERAL: BLT: A new 2013 research report extends the benefit of BLIS K12
A new 2013 research report extends the benefit of BLIS K12(TM) probiotic
BLIS Technologies Ltd (NZX:BLT) announces another clinical study, just
published this month, which further supports the effectiveness of BLIS
K12(TM) oral cavity probiotic for preventing ear and throat infections.
Published in the medical science journal, Expert Opinion on Biological
Therapy, an Italian research team demonstrated that they could prevent the
reoccurrence of common ear and throat infections, such as strep throat
infection and tonsillitis by more than 83% in adults. The study followed 40
adults with a history of recurrent ear and throat infection and examined the
effect of 90 days of treatment with either the BLIS K12(TM) probiotic or a
placebo. Researchers concluded "The regular use of BLIS K12 appears to have
effected a substantial reduction in the incidence of recurrent oral
streptococcal pathology, reducing the requirement for these BLIS K12-treated
individuals to be exposed to therapeutic courses of antibiotics."
Di Pierro, F., et al. (2013). Clinical evaluation of the oral probiotic
Streptococcus salivarius K12 in the prevention of recurrent pharyngitis
and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opinion
on Biological Therapy.
This paper has been published just two months after a similar research paper
also concluded that regular use of BLIS K12 in children could reduce the
incidence of strep throat infection (including tonsillitis) by more than 92%.
The children examined in this earlier study, previously had a recurrence rate
for strep throat infection of nearly 4 times per year, however those children
who then were assigned to the treatment with the BLIS K12(TM) probiotic
dropped dramatically their rate of infection to the equivalent of just one
incidence, every 4 years.
BLIS Technologies CEO, Dr Barry Richardson said, "We have known from our own
work over several years about the effectiveness of the BLIS K12(TM) probiotic
in treating and preventing certain infections of the throat and upper airways
but finally, we have an independent research group that has now corroborated
these findings. It is reassuring to us to know that BLIS K12(TM) has been
independently supported as being highly efficacious in both children and
adults."
Dr Richardson said that he has seen a growing awareness among healthcare
professional in New Zealand, pharmacists, dentist and doctors of benefits of
BLIS K12(TM) probiotic for mouth and throat and has seen an increasing
acceptance to consider BLIS K12(TM) probiotic as an option when managing the
health of their patients, both young and old.
YOUR CONTACT:
Dr Barry Richardson
BLIS Technologies Ltd
PO Box 56 ?87 St David Street ?Dunedin?New Zealand
Phone +64 (3) 479 5337
www.blis.co.nz
End CA:00231971 For:BLT Type:GENERAL Time:2013-01-11 14:09:14
